abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 02월 28일 17시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제123회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Core Competences in the Biopharmaceutical Development

등록일
2019년 2월 13일 10시 38분 52초
접수번호
4035
발표코드
LIFE1-1 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 15시 : 40분
발표형식
심포지엄
발표분야
Life Chemistry - Recent Trends in Biopharmaceuticals Research
저자 및
공동저자
Young-Phil Lee
Samsung Bioepis, Korea
The biopharmaceuticals account for 27% of the pharmaceutical market. Moreover, seven biopharmaceuticals are listed on the top 10 best-selling drugs. However, such seemingly promising market presents obstacles for market entry. Larger molecular weight of biopharmaceuticals in comparison to that of synthetic drugs makes biopharmaceuticals difficult to develop manufacturing processes and more vulnerable to quality changes by subtle process changes. Topping off the developmental hurdles, the pharmaceutical sector is one of the most regulated industries. Hence, in order to link science and knowledge gained from basic research to commercialization, it is necessary not only to overcome developmental hurdles, but also to obtain a marketing approval in compliance with the regulations of health authorities.
Until now, most domestic pharmaceutical and bio-venture companies have repeatedly taken a cycle of licensing out candidate drugs to global pharmaceutical companies in the early stages due to lack of global development capabilities and experience and limited development costs. Under such circumstances, Samsung Bios and Celltrion have been striving to establish the commercialization capabilities of biopharmaceuticals in Korea, and achieved great success comparable to global standards in terms of the development, production and regulatory approval. Established in 2012, Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars. Samsung Bioepis has launched 4 biosimilar products in Europe and in the U.S over the past 6 years. In this session, I will review the core competencies of Samsung Bioepis and present a vision to promote symbiosis for the globalization of the Korean pharmaceutical industry.

상단으로